CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events
Item8.01.Other Events
On June7, 2017, CRISPR Therapeutics AG announced the hiring and
appointment of James R. Kasinger as its General Counsel and
Secretary to the Board of Directors. A copy of the press release
announcing Mr.Kasingers appointment is attached hereto as Exhibit
99.1.
Item9.01.Financial Statements and Exhibits.
(d)Exhibits:
|
ExhibitNo. |
Description |
|
| 99.1 | Press Release by CRISPR Therapeutics AG, dated June 7, 2017 |
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.
